Drug Trial Radar · NCT00077636
ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
Last checked: Nov 20, 2026Latest source record: Feb 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,469
Actual
Start
Dec 2003
Primary completion
Mar 2006
Study completion Mar 2006
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Feb 13, 2004
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.
Conditions
- Hepatitis C, Chronic
Interventions
CopegusDrug
400mg po bid for 16 weeks
CopegusDrug
400mg po bid for 24 weeks
peginterferon alfa-2a [Pegasys]Drug
180 micrograms sc weekly for 16 weeks
peginterferon alfa-2a [Pegasys]Drug
180 micrograms sc weekly for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Sustained Virological Response (SVR)Time frame: Week 40 (for 16-week treatment group); Week 48 (for 24-week treatment group)
Locations
132 sites in 9 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mobile, Alabama
Site not named
Anchorage, Alaska
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Little Rock, Arkansas
Site not named
La Jolla, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Palo Alto, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
San Francisco, California
Site not named
San Luis Obispo, California
Site not named
Littleton, Colorado
Site not named
Farmington, Connecticut
Site not named
Bradenton, Florida
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Pensacola, Florida
Site not named
Tampa, Florida
Site not named
Wellington, Florida
Site not named
Atlanta, Georgia
Site not named
Austell, Georgia
Site not named
Honolulu, Hawaii
Site not named
Boise, Idaho
Site not named
Moline, Illinois
Site not named
Indianapolis, Indiana
Site not named
Iowa City, Iowa
Site not named
Iowa City, Iowa
Site not named
Baton Rouge, Louisiana
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Baltimore, Maryland
Showing 40 of 132 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.